Search Results
Apr 22, 2026, 16:35 ET Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 10, 2026, 07:30 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 09, 2026, 19:50 ET Zebra Technologies and Aiva Health Announce Partnership to Power Hands-Free Nurse Workflows
via ServiceNow®Access to Clinical Policies & ProceduresVoice-initiation of Clinical Interpretation Sessions: LanguageLine® and AMN Healthcare®When paired with Zebra's HC20/HC50 mobile computers, nurses can use Aiva alongside familiar mobile workflows. With Zebra's new
More news about: Aiva, Inc.
Apr 01, 2026, 16:15 ET SIKORA Unveils Three New Product Innovations for the Wire and Cable Industry
Pulverizing Systems, Recycling Systems and Measurement & Control Systems divisions consolidate the many years of experience and in-depth know-how of the AMN, AUTOMATIK, ETTLINGER, GALA, MAAG, REDUCTION, SCHEER, SIKORA, WITTE and XANTEC product brands. The MAAG Group currently employs over 1,900 people at
More news about: Dover
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Mar 24, 2026, 09:00 ET Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
report seeing more AI-informed patients over the past year. Access is a key driver: with national wait times exceeding 31 days on average (source: AMN Healthcare), 65% of patients say they've used AI because it's easier than seeing a doctor.Yet many patients aren't telling their doctors.
More news about: Zocdoc
Mar 24, 2026, 09:00 ET Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
report seeing more AI-informed patients over the past year. Access is a key driver: with national wait times exceeding 31 days on average (source: AMN Healthcare), 65% of patients say they've used AI because it's easier than seeing a doctor.Yet many patients aren't telling their doctors.
More news about: Zocdoc
Mar 17, 2026, 15:02 ET Group Management Services Appoints Beth Harhai as Chief Revenue Officer to Drive Strategic Growth
advising on go‑to‑market strategy for an emerging health‑tech company.Previously, Harhai held senior leadership roles at organizations including AMN Healthcare, where she oversaw a national sales organization, as well as DeliverHealth, Blackbaud, Healthgrades (acquired by WebMD), and Allscripts.
More news about: Group Management Services, Inc.
Mar 05, 2026, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Feb 04, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 07, 2026, 07:00 ET Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 16:03 ET Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Dec 10, 2025, 08:00 ET Trend Micro Honors Global Leaders in Cybersecurity with 2025 Global Customer Awards
realize this strategy and vision. Now we have a single pane of glass view, and one click control that wasn't possible before."Mani Masood, CISO, AMN Healthcare: "Cyber resilience is built by anticipating change before it becomes a crisis. Security leadership is the ability to make tomorrow's risks
More news about: Trend Micro Incorporated
Dec 10, 2025, 06:00 ET Zocdoc Reveals Evolving Patient Preferences and Trends in Third Annual What Patients Want Report
to average) included plastic surgery consultations, filler, and anti-aging treatmentsPatients prize speed to careDespite AMN Healthcare reporting that national average wait times have increased to 31 days (up from 26 in 2024), patients on Zocdoc moved fast and were seen fast:
More news about: Zocdoc Inc.
Nov 25, 2025, 16:05 ET Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 19, 2025, 02:55 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 06, 2025, 07:05 ET Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 04, 2025, 16:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 29, 2025, 16:05 ET Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 15, 2025, 16:05 ET Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.